fr   en
Clinical Studies

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2009-12-17
Phase: III
Anouncement: Launch
Biotech:
Pharma: Boehringer Ingelheim (Germany)
Product: BIBF1120 (Vargatef®) This oral anti-angiogenic agent works by simultaneously inhibiting three receptors involved in angiogenesis.
Disease: ovarian cancer
Country:
Other: Boehringer Ingelheim has announced the broadening of its clinical trial programme for its investigational cancer compound BIBF1120. A new phase III clinical trial has been initiated to evaluate the compound for the treatment of patients with advanced ovarian cancer.
The clinical study, called LUME-Ovar-1 trial, investigates BIBF 1120, for its efficacy and safety as first-line treatment in combination with standard chemotherapy compared to placebo in combination with standard chemotherapy in patients with advanced ovarian cancer.
This intergroup study is conducted by an international consortium of study groups led by the AGO Study Group (Arbeitsgemeinschaft Gynaekologische Onkologie Study Group, Germany), and Boehringer Ingelheim.